September 17, 2019 / 5:24 AM / a month ago

BRIEF-Novartis Says Phase III PREVENT Study Met Primary Endpoint For Patients With Axial Spondyloarthritis

Sept 17 (Reuters) - Novartis AG:

* NOVARTIS COSENTYX® POSITIVE 16-WEEK PREVENT RESULTS ADVANCE POTENTIAL NEW INDICATION FOR PATIENTS WITH AXIAL SPONDYLOARTHRITIS

* PHASE III PREVENT STUDY MET 16-WEEK PRIMARY ENDPOINT OF ASAS40 IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)

* ALL SECONDARY ENDPOINTS WERE ALSO MET

* NOVARTIS HAS SUBMITTED TO EMA FOR APPROVAL IN NR-AXSPA, WHICH WOULD BE FOURTH INDICATION FOR COSENTYX

* 52-WEEK DATA FROM PREVENT STUDY, TO SUPPORT FDA SUBMISSION, ARE EXPECTED LATER IN YEAR Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below